MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.radonc.2026.111490

Медицинская библиотека · Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026

Conventional vs. hypofractionated radiotherapy for high-risk prostate cancer (PCS5), randomized, non-inferiority, phase III trial: Post hoc analysis of radiation therapy toxicities and efficacy of IMRT compared to 3D-CRT.

Martínez Constanza, Tisseverasinghe Steven, Karim Muneeb U, Ka Kanta, Nabid Abdenour, Kaldany Edmond, Bettahar Redouane, Vincent Linda, Martin Andre-Guy, Jolicoeur Marjory, Yassa Michael, Barkati Maroie, Bahoric Boris, Archambault Robert, Villeneuve Hugo, Mohiuddin Mohammed, Niazi Tamim

СтатьяКлиническое исследование III фазыРандомизированное исследованиеСравнительное исследованиеEquivalence TrialПеревод в очереди

Аннотация

PURPOSE: Prostate Cancer Study 5 (PCS-5) is a phase III, randomized controlled trial comparing conventionally fractionated radiotherapy (CFRT) vs. hypofractionated radiotherapy (HFRT) exclusively in patients with high-risk prostate cancer (PCa). This post hoc analysis evaluates differences in efficacy outcomes as well as genitourinary (GU) and gastrointestinal (GI) toxicities between intensity-modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3D-CRT).

MATERIALS AND

METHODS

PCS-5 randomized patients in a 1:1 ratio to CFRT (76 Gy in 38 fractions) or HFRT (68 Gy in 25 fractions). All patients received long-term androgen suppression (median duration: 24 months) and pelvic radiation therapy (RT). Acute toxicities were defined as ≤ 180 days post-RT, and delayed toxicities > 180 days using CTCAE v4. Multivariable logistic regression analyses were performed for acute and delayed toxicities, adjusting for clinical factors. Efficacy analyses utilized Cox proportional hazards regression models.

RESULTS

Among 329 patients, 296 were included in this study. IMRT reduced acute G2 + GI toxicities (OR 0.50; 95% CI, 0.29-0.91; p = 0.023), delayed G2 + GI toxicities (OR 0.36; 95% CI, 0.16-0.82; p = 0.015), and increased acute G1 + GU toxicities (OR 1.77; 95% CI, 1.07-2.95; p = 0.03) compared to 3D-CRT. Biochemical failure-free survival, distant metastasis-free survival, and overall survival did not significantly differ between techniques.

CONCLUSION

In PCS-5, HFRT is a standard treatment for high-risk PCa receiving external beam RT. In this post hoc analysis, IMRT was associated with lower acute and delayed G2 + GI toxicity than 3D-CRT, with a modest increase in acute G1 + GU toxicity and no differences in efficacy. Within the limitations of this non-randomized comparison, IMRT appears to be the preferred technique.

Для цитирования: Martínez Constanza, Tisseverasinghe Steven, Karim Muneeb U, Ka Kanta, Nabid Abdenour, Kaldany Edmond, Bettahar Redouane, Vincent Linda, Martin Andre-Guy, Jolicoeur Marjory, Yassa Michael, Barkati Maroie, Bahoric Boris, Archambault Robert, Villeneuve Hugo, Mohiuddin Mohammed, Niazi Tamim. Conventional vs. hypofractionated radiotherapy for high-risk prostate cancer (PCS5), randomized, non-inferiority, phase III trial: Post hoc analysis of radiation therapy toxicities and efficacy of IMRT compared to 3D-CRT.. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2026. DOI: 10.1016/j.radonc.2026.111490.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.